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and gender-specific as well as severity-based prevalence fig-
ures for PD in Germany. Further community studies are 
needed to estimate population-based severity distributions 
and distributions of non-motor symptoms in PD.
© 2017 S. Karger AG, Basel
Introduction
Parkinson’s disease (PD), as the second most common 
neurodegenerative disorder [1], is clinically not only 
characterized by its hallmark of motor symptoms, but 
also by a range of non-motor symptoms including auto-
nomic, cognitive, affective, and behavioral manifesta-
tions [2, 3]. The non-motor symptoms of PD have been 
shown to contribute to increased disability and suffering, 
poorer prognosis, and quality of life decrements of pa-
tients and their families as well as PDs considerable eco-
nomic burden [4, 5].
Although crude epidemiological information about 
PD exist for Germany, the number of solid state-of-the-
art prevalence studies in Germany is very limited and 
findings can hardly be generalized to the entire popula-
tion [6]. More precisely, we identified only 4 studies from 
the early 1990s [6–9], which are methodologically hetero-
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Abstract
Background: Epidemiological data on the prevalence of Par-
kinson’s disease (PD) in Germany are limited. The aims of this 
study were to estimate the age- and gender-specific preva-
lence of PD in Germany as well as the severity and illness 
duration. Summary: A systematic literature search was per-
formed in 5 different databases. European studies were in-
cluded if they reported age- and gender-specific numbers of 
prevalence rates of PD. Meta-analytic approaches were ap-
plied to derive age- and gender-specific pooled prevalence 
estimates. Data of 4 German outpatient samples were incor-
porated to calculate the proportion of patients with PD in 
Germany grouped by Hoehn and Yahr (HY) stages and dis-
ease duration. In the German population, 178,169 cases of 
PD were estimated (prevalence: 217.22/100,000). The esti-
mated relative illness duration was 40% with less than 
5 years, 31% with 5–9 years, and 29% with more than 9 years. 
The proportions for different HY stages were estimated at 
13% (I), 30% (II), 35% (III), 17% (IV), and 4% (V), respectively. 
Key Message: We provide an up-to-date estimation of age- 
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geneous, limited in its scope and detail and provide high-
ly variable results [10]. Thus, it is difficult to estimate the 
disease burden caused by PD as well as to specify what 
proportion of the population is affected by different de-
grees of severity and the degree of met and unmet needs 
for diagnosis and treatment. The lack of appropriate and 
detailed epidemiological data is a particular barrier for 
rational planning and the allocation of resources as well 
as for prioritizing research policies. In the case of PD as a 
chronic progressive disorder [11, 12], this is related par-
ticularly to the yet unmet need for reliable epidemiologi-
cal figures including distributions of severity stages or 
disease duration.
A widely used measure of the severity of PD is the 
Hoehn and Yahr (HY) rating scale, which provides a 
crude but clinically meaningful symptom-based measure 
of the disease progression [13]. Unfortunately, only a few 
European and none of the German studies has reported 
prevalence estimates of PD stratified according to HY 
stages or disease duration [10].
This study makes an attempt to fill this important gap 
of knowledge by providing prevalence estimates of PD 
by HY stages and disease duration using a mixed meth-
od approach. Using a meta-analytic approach of Euro-
pean epidemiological studies, we first provide consoli-
dated age- and gender-specific prevalence estimates of 
PD in Germany. Then, we link the estimated age- and 
gender-specific prevalence with appropriate German 
databases containing information on clinically well-de-
fined outpatients with PD to provide estimates of the 
prevalence pattern of PD by HY stages and illness dura-
tion.
Methods
Based on a systematic literature review of European studies to 
identify relevant data sources, we first pooled the available study 
data separately by age and gender to derive prevalence estimates of 
PD by age and gender. In the second step, these prevalence data 
were then transformed into ‘number of persons affected’ by using 
the respective age- and gender-specific population registry data for 
Germany as of December 31, 2013. In the third step, we standard-
ized available data by age and gender from 4 German samples of 
outpatients with PD that have provided information about HY 
stages and illness duration by age and gender using the expected 
population of patients with PD in Germany as the reference popu-
lation. These standardized relative frequencies were then used to 
compute a pooled estimate. Details of the study methods are de-
scribed below.
Data Sources and Data Extraction
The primary source for the literature data was a systematic re-
view by von Campenhausen et al. [10] that included studies based 
on primary data reporting the prevalence and incidence of PD in 
Europe from 1966 until 2004. The systematic review comprised 44 
studies estimating prevalence or incidence rates of PD of which 21 
studies reported age- and gender-specific prevalence as well as the 
size of the underlying population [14–34]. To supplement these 
data by studies that were published after 2004, an additional sys-
tematic literature search was performed using the same search 
strategy as described by von Campenhausen et al. [10] (Fig.  1). 
Four studies which provided data on age- and gender-specific 
Articles identified in MEDLINE, the
COCHRANE’s database of systematic
reviews, EconLit, Web of science, and
EMBASE
(n = 115)
Articles screened for numbers on
prevalent cases of Parkinson’s disease
(n = 23)
 Articles excluded (n = 19)
• Only numbers on incident cases of Parkinson’s
 disease reported (n = 13)
• No age-and gender-specific number on
 prevalent cases of Parkinson’s disease (n = 6)
 Articles excluded (n = 92)
• Not published in German of English language
 (n = 3)
• Non-European studies (n = 71)
• No primary data on prevalence/incidence of
 Parkinson’s disease (n = 16)
• Duplicates (n = 2)
Articles added to meta-analysis
(n = 4)Fig. 1. Added studies from the literature 
update after 2004.
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prevalence were additionally included [35–38]. Thus, 25 studies 
were eligible for further analyses.
From each study, age- and gender-specific numbers were ex-
tracted by 2 independent reviewers. Study design, country, and 
quality of the studies were determined. Following the recommen-
dations proposed by von Campenhausen et al. [10], a study was 
called a high quality study, if an established diagnostic criterion 
was used to identify cases of PD and the screening was conducted 
by neurologists [10].
Information on the distribution of the duration and severity of 
disease among patients with PD in Germany was obtained from 
4 outpatient samples (Table 1). In each sample, the duration of the 
disease was measured as the time from beginning of the symptoms 
until the examination date, categorized into <5, 5–9, and >9 years. 
The disease severity was assessed using the 5 stages of the HY scale 
[13].
Statistical Analyses
Findings from eligible studies were extracted and pooled prev-
alence estimates with 95% CI were computed for each age and 
gender category from the individual studies. Age- and gender-
specific prevalence estimates were calculated for all studies pro-
viding numbers for the specific age and gender category. These 
estimates were transformed using the Freeman-Tukey double arc-
sine function to stabilize their variances [39]. A pooled prevalence 
with a 95%-CI was calculated assuming a random effects model 
for the transformed prevalence, because there was indication of 
heterogeneity in most of the age and gender categories. The 
pooled prevalence was transformed back using the inverse of the 
Freeman-Tukey double arcsine function. This function requires 
the specification of a sample size for the pooled prevalence, which 
was assumed to be the sum of the individual study populations 
[40].
The expected number of cases with PD in Germany was cal-
culated by multiplying age- and gender-specific population 
counts of the German population using the total population reg-
istry data for Germany as of December 31, 2013 [41] with the 
pooled prevalence estimations in the respective age and gender 
category. Since the existing German studies partly reported 
 prevalence of PD in the population aged 65 years and above, the 
prevalence of PD in the German population aged 65 years and 
above was calculated for comparison purposes too. Therefore, 
the meta-analysis was repeated with studies reporting gender-
specific numbers on study population and prevalent cases in at 
least one of the following age categories: 65–74, 75–84, and 
≥85 years.
A meta-analysis was performed to obtain pooled relative fre-
quencies of patients with PD in Germany in categories of dis-
ease severity and disease duration based on the 4 outpatient sam-
ples: 
(i) The relative frequency of patients in the respective category 
in each outpatient sample was standardized with respect to age and 
gender using the expected number of cases of PD in Germany as 
the standard population, since the distribution of age and gender 
might differ between the selective outpatient samples and the PD 
population in Germany. In addition, severity and disease duration 
of PD are likely to be associated with age. Since frequencies might 
be low for some categories, the variance of the standardized rela-
tive frequency was calculated based on the Poisson approximation 
[42].
(ii) A pooled relative frequency was calculated assuming a ran-
dom effects model for the standardized relative frequencies across 
the 4 outpatient samples, since there was no indication of hetero-
geneity in most of the categories of the duration of PD and the HY 
stages. Since the sum of the pooled relative frequencies over all 
categories may not equal one, the relative frequencies were divided 
by the sum of the pooled relative frequencies for the duration of 
the disease and the HY stages, respectively.
In each random effects model, the between-study variance was 
estimated using the method of DerSimonian-Laird [43] and het-
erogeneity was assessed with the I2-statistic (a value above 60% 
indicating heterogeneity) [44].
Table 1. Outpatient samples of patients with PD providing data on duration and severity of disease
Sample Number of 
patients
Recruitment criteria Reference
GEPAD 1,449 Random sample of patients recruited between 
September and October 2005 from a representative 
sample of 315 office-based neurologists in Germany
Riedel et al. [5], 2008; 
Riedel et al. [50], 2010;
Riedel et al. [51], 2010
KNP 145 Patients from North Hessia recruited between the 
first and second quarter of 2000 by an outpatient 
department for movement disorders, a specialized PD 
clinic, 2 office-based neurologists, and 12 general 
practitioners
Spottke et al. [52], 2005
NeuroPa 425 Patients of 12 specialized office-based neurologists in 
Berlin recruited in the fourth quarter of 2006
Ehret et al. [7], 2009
QUANUP 234 Random sample of patients of 21 office-based 
neurologists
Unpublished data
PD, Parkinson’s disease.
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Results
Prevalence of PD in Germany
Of the 25 studies providing age- and gender-specific 
prevalence estimates, numbers in at least one of the age 
categories <50, 50–59, 60–69, 70–79 or ≥80 years could be 
extracted from 21 studies (Table 2). A total of 10 of these 
studies were conducted in Italy [16, 17, 19, 23, 24, 26, 28–
30, 35], followed by 6 studies in the United Kingdom [27, 
31–33, 36, 38]. Notably, none of the studies were conduct-
ed in Germany. Of these, 4 were conducted using a door-
to-door design [14, 18, 24, 26] and 12 of the studies were 
cross-sectional based on medical records [16, 19, 22, 25, 
27, 31–36, 38], and 3 of the studies were assigned a low 
quality [22, 31, 38]. The pooled prevalence estimates for 
all age and gender categories are displayed in Table 3. Us-
ing the age and gender distribution of the total German 
population as of December 31, 2013, 178,169 prevalent 
cases are expected, corresponding to a prevalence estimate 
of 217.22/100,000. The age- and gender-specific distribu-
tions of the expected prevalent cases of PD are also dis-
played in Figure 2. Using the lower and upper limits of the 
CIs for the expected cases of PD in each age and gender 
category, a lower extreme prevalence estimate of 
173.76/100,000 and an upper extreme prevalence estimate 
of 265.80/100,000 for the total German population are ob-
tained. Using these prevalence estimate, in the German 
population, 1,829 cases (1.0% of all PD cases) under 50 
years, 15,456 cases (8.7%) between 50 and 59 years, 31,754 
cases (17.8%) between 60 and 69 years, 72,536 cases 
(40.7%) between 70 and 79 years, and 56,594 cases (31.8%) 
greater or equal than 80 years are expected. The expected 
numbers of prevalent cases by gender were 87,803 men 
(prevalence 217.62/100,000) and 90,366 women (preva-
lence 216.84/100,000). Although the prevalence is higher 
in men than in women across all age categories, the esti-
mated overall prevalence in women and men are similar 
due to the higher life expectancy and consequently the 
higher proportion of women in the ages above 70 years.
A sum of 11 studies reported prevalences in at least one 
of the age categories 65–74, 75–84, and ≥85 years [14–16, 
19–21, 24, 27, 32, 36, 37]. Using only these studies in the 
meta-analysis, a pooled prevalence of 1,078.71/100,000 
was estimated for the German population aged 65 years 
and above.
Duration of PD and Disease Severity
The relative frequencies of the duration of PD and the 
HY stages as well as the age- and gender-standardized 
figures with 95% CIs are displayed in Table 4. The stan-
dardization generally resulted in small changes concern-
ing the duration of the disease. However, throughout all 
samples, the relative frequencies of the HY stages I and II 
was decreased and the relative frequency of the HY stage 
V was increased after the standardization.
The pooled estimates of the relative disease duration 
of PD was as follows: 0.40 95% CI (0.27–0.52) with less 
than 5 years, 0.31 95% CI (0.28–0.34) with 5–9 years, and 
0.29 95% CI (0.19–0.40) with more than 9 years. The 
pooled estimates of the relative frequency of the HY-stag-
es were as follows: 0.13 95% CI (0.10–0.17) at stage I, 0.30 
95% CI (0.27–0.33) at stage II, 0.35 95% CI (0.25–0.46) at 
stage III, 0.17 95% CI (0.15, 0.20) at stage IV, and 0.04 
95% CI (0.01, 0.06) at stage V.
Discussion
Given the need for clinically detailed data about the 
number of PD cases in Germany by duration and sever-
ity and being aware that it is unlikely that such a major 
epidemiological study program will become reality in the 
near future, we applied a meta-analytic approach to pro-
vide such crucial information as a time- and cost-efficient 
alternative. Our age- and gender-specific estimates of the 
prevalence of PD in Germany are more detailed and com-
prehensive as estimates provided by the single studies 
conducted in Germany so far and can be seen as being 
most likely a more accurate reflection of the true preva-
lence and the true number of cases affected. Our addi-
tional stratification by disease severity and duration adds 
to the clinical relevance and utility. Neither the exclusion 
of individual studies nor the restriction to high quality 
studies had a high impact on the pooled prevalence esti-
mates (data available at request).
Referring to the total German population as of Decem-
ber 31, 2013, we estimated a total prevalence of PD in 
Germany of 217.22/100,000 with a range of uncertainty 
between 173.76 and 265.80/100,000. For the population 
aged 65 years and above, a prevalence of 1,078.71/100,000 
was estimated. This findings agree relatively well with 
2 German high-quality, cross-sectional studies conduct-
ed by Vieregge et al. [6] and Trenkwalder et al. [9] that 
reported prevalence estimates of 183/100,000 in a rural-
urban area of Northern Germany and 713/100,000 in pa-
tients over the age of 65 years in a rural area of Bavaria. 
Our estimates were slightly higher but were in a similar 
order of magnitude. Our results are further in agreement 
with a recently conducted study based on claims data 
from German health insurances, which estimated the 
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Table 2. Studies included in the meta-analysis
Study Country Design Quality* Population 
size
Prevalent men (number of men in the study)/prevalent women (number of 
women in the study)
<50 years 50–59 years 60–69 years 70–79 years ≥80 years
Benito-Leon, 
et al. [14]
Spain Door-to-Door High 5,278 28 (1,024)/
13 (1,342)
8 (475)/
24 (786)
Casetta, 
et al. [16]
Italy Cross-sectional High 38,360 2 (12,966)/
1 (12,549)
1 (2,539)/
1 (2,674)
5 (1,826)/
8 (2,151)
Chio, et al. [17] Italy Consumption High 61,830 0 (18,672)/
0 (17,946)
6 (4,200)/
4 (4,476)
16 (3,710)/
8 (4,617)
22 (2,004)/
21 (3,145)
11 (912)/
16 (2,108)
Claveria, 
et al. [18]
Spain Door-to-Door High 3,503 0 (181)/
0 (205)
1 (240)/
2 (239)
3 (149)/
1 (169)
7 (43)/
6 (99)
D’Alessandro, 
et al. [19]
Italy Cross-sectional High 22,322 4 (944)/
5 (980)
11 (600)/
10 (773)
1 (206)/
2 (339)
Errea, et al. [22] Spain Cross-sectional Low 60,724 0 (18,647)/
2 (17,026)
4 (3502)/
3 (3,487)
21 (4,442)/
17 (4,282)
29 (2,633)/
28 (3,346)
16 (1,339)/
14 (2,021)
Granieri, 
et al. [23]
Italy Longitudinal High 176,621 23 (12,979)/
29 (14,859)
43 (9,444)/
38 (11,787)
53 (5,927)/
38 (8,702)
Kis, et al. [24] Italy Door-to-Door High 750 2 (173)/
1 (238)
4 (127)/
4 (147)
Marttila and 
Rinne [25]
Finland Cross-sectional High 402,988 8 (150,180)/
5 (151,667)
27 (19,824)/
27 (25,592)
88 (17,478)/
121 (24,283)
56 (7,608)/
116 (13,988)
8 (1,721)/
28 (4,342)
Morgante,
 et al. [26]
Italy Door-to-Door High 19,955 0 (9,007)/
0 (8,707)
2 (1,261)/
1 (1,335)
6 (969)/
7 (1,123)
12 (708)/19 
(859)
7 (214)/
9 (314)
Morgante, 
et al. [35]
Italy Cross-sectional High 13,431 0 (4,710)/
0 (4,361)
1 (780)/
1 (736)
1 (710)/
1 (723)
3 (417)/
3 (572)
2 (153)/
2 (269)
Mutch, 
et al. [27]
United 
Kingdom
Cross-sectional High 151,616 9 (8,983)/
6 (10,336)
26 (7,204)/
16 (9,332)
51 (4,536)/
54 (7,969)
16 (1,069)/
63 (3,036)
Porter, et al. [36] United 
Kingdom
Cross-sectional High 108,597 1 (34,381)/
0 (35,715)
5 (6,921)/
3 (7,045)
16 (5,316)/
17 (5,816)
38 (3,880)/
44 (5,219)
14 (1,408)/
23 (2,896)
Rosati, 
et al. [28]
Italy Longitudinal High 397,891 34 (17,259)/
36 (17,789)
55 (16,576)/
52 (17,499)
50 (8,557)/
40 (10,857)
Rosati, 
et al. [30]
Italy Longitudinal High 273,421 28 (10,753)/
21 (11,959)
44 (11,120)/
37 (12,231)
21 (6,610)/
14 (7,701)
Rosati, 
et al. [29]
Italy Longitudinal High 1,473,800 144 (61,776)/
113 (63,878)
225 (58,185)/
184 (61,374)
121 (29,788)/
87 (37,037)
Schrag, 
et al. [31]
United 
Kingdom
Cross-sectional Low 121,608 4 (44,848)/
0 (46,140)
9 (6,207)/
4 (5,714)
19 (4,289)/
10 (4,184)
29 (2,810)/
32 (3,540)
21 (1,266)/
28 (2,607)
Sutcliffe, 
et al. [33]
United 
Kingdom
Cross-sectional High 208,499 2 (66,667)/
2 (66,667)
10 (10,870)/
4 (11,111)
26 (9,155)/
27 (10,000)
46 (5,436)/
47 (7,781)
21 (1,624)/
41 (3,832)
Sutcliffe and 
Meara [32]
United 
Kingdom
Cross-sectional High 302,500 21 (15,589)/
7 (14,710)
40 (12,994)/
29 (14,474)
89 (8,803)/
63 (11,495)
50 (3,200)/
81 (7,300)
Taba and 
Asser [34]
Estonia Cross-sectional High 153,240 2 (53,132)/
2 (53,092)
10 (7,683)/
12 (9,662)
25 (6,267)/
52 (9,367)
35 (2,813)/
78 (6,356)
16 (1,244)/
38 (3,624)
Wickremaratchi 
et al. [38]
United 
Kingdom
Cross-sectional Low 292,637 4 (106,487)/
1 (101,006)
14 (16,901)/
10 (15,348)
38 (11,616)/
25 (11,539)
68 (8,193)/
61 (9,288)
74 (4,413)/
85 (7,846)
* A high quality study must report the use of an established diagnostic criterion to identify cases of PD and a screening of cases of PD by neurologists.
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prevalence in the German population aged 65 years and 
older as 1,680/100,000. Although this study had a large 
sample size and covers all regions of Germany, the com-
parability with our results is somewhat limited due to 
general differences between primary and secondary data 
sources (e.g., case ascertainment) [45].
The results of our meta-analysis further suggest 3 oth-
er noteworthy findings. (i) The age-specific prevalence of 
PD in men is moderately higher than in women. There is 
growing data on biological reasons for gender differences 
in PD [46, 47] but they are not yet fully understood. (ii) 
PD prevalence is considerably age dependent. The preva-
lence ranges from 3.82/100,000 in the youngest age group 
(below 50 years) to 1,273.58/100,000 in the age group 
above 80 years. (iii) There were enough studies to esti-
mate the prevalence of PD in the population younger 
than 60 years. Further analyses of the age groups <50 
years and 50–59 years indicated that the prevalence of PD 
in these age groups might be decreasing since the 1980s 
and differ between countries (we compared United King-
dom and Italy only because all other countries provided 
at most 1 study for these age groups), although the small 
number of events in these age groups precludes statisti-
cally secured conclusions (Table 5).
Community surveys as a variant of general population 
survey (“door-to-door”) studies are assumed to be the gold 
standard for prevalence estimation, since these studies de-
tect cases that would not have been recognized in other 
study designs, for example, in cross-sectional studies. 
However, the identified door-to-door studies have rela-
tively small sample sizes and numbers of cases, leading to 
increased uncertainty in the prevalence estimation. In this 
meta-analysis, only 4 door-to-door studies could be in-
cluded precluding a restriction to door-to-door studies. 
Nevertheless, a limitation of this meta-analysis is that the 
prevalence estimates for PD in Germany were mostly based 
on data from cross-sectional studies based on medical re-
cords and might therefore lead to an underestimation.
Table 3. Expected patients with PD in the German population
Age, years Gender German population Pooled prevalence of PD/
100,000 (95% CI)
Expected cases of PD (95% CI)
<50 Male
Female
24,375,140
23,323,134
4.86 (3.13–6.99)
2.76 (1.49–4.41)
1,185 (763–1,697)
644 (348–1,029)
50–59 Male
Female
6,156,469
6,102,406
146.46 (116.98–179.24)
105.52 (77.34–138.05)
9,017 (7,202–11,035)
6,439 (4,720–8,424)
60–69 Male
Female
4,401,202
4,652,554
385.76 (352.87–420.09)
317.58 (266.21–373.46)
16,978 (15,531–18,489)
14,776 (12,386–17,375)
70–79 Male
Female
3,876,835
4,668,244
1,001.77 (803.89–1,221.15)
721.88 (555.03–910.43)
38,837 (31,165–47,342)
33,699 (25,910–42,501)
≥80 Male
Female
1,537,207
2,927,387
1,417.22 (1,103.10–1,769.94)
1,189.03 (940.73–1,465.96)
21,786 (16,957–27,208)
34,808 (27,539–42,914)
All ages Male
Female
40,346,853
41,673,725
87,803
90,366
Both 82,020,578 178,169
PD, Parkinson’s disease.
0
5,000
10,000
15,000
20,000
25,000
30,000
35,000
40,000
45,000
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<50 50–59 60–69 70–79 ≥80
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Fig. 2. Expected cases of Parkinson’s disease (PD) in Germany by 
age and gender.
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Our study underlies the assumption that the preva-
lence of PD is comparable between European countries. 
A further limitation is thus the lack of diversity in the 
countries providing prevalence estimates. The prevalence 
of PD might differ between countries, for example, be-
cause of environmental factors and life expectancy. Since 
mainly Italy, Spain, and the United Kingdom were pro-
viding age- and gender-specific prevalence estimates, a 
pattern in the prevalence across the European countries 
could not be identified and it remained unclear if an ex-
trapolation to Germany is valid. Unfortunately, PD prev-
alence estimates in the included studies of the meta-anal-
ysis were mostly reported only stratified by age and gen-
der. This precludes the investigation of other risk factors 
of PD prevalence besides age and gender.
Using 4 outpatient samples, we also determined PD 
patient proportions for duration groups and HY severity 
stages. Consistent with the chronic progressive character 
of PD, we estimated that the disease duration was rela-
tively long, that is, more than 10 years, in 29% of the PD 
patients. However, information on disease duration was 
obtained from patient records and may therefore be inac-
curate due to patient-reported onset dates. Nevertheless, 
given accurate records of disease duration, we estimated 
that about at least one-third of the PD patients survive 
more than 10 years. By comparing these proportions with 
the distribution of the HY stages, we concluded that a 
non-negligible number of patients are long-term survi-
vors with a slow progression of the disease and thus may 
not reach the highly disabling late stage PD (defined as 
HY stages IV and V) [48, 49]. External data to validate the 
distribution of the duration of the disease is missing in the 
literature.
In our study, we estimated a low disease severity (HY 
stage I or II) in 43% of the PD patients. This proportion 
is smaller than in most of the studies identified by the re-
view of von Campenhausen et al. [10]. Of the 5 studies 
that reported relative frequencies of the HY stages, 4 stud-
ies classified 55% and 1 study classified 27% of the pa-
tients in HY stages I or II. However, since the distribution 
differed substantially between the 5 studies, a comparison 
of the studies is not feasible.
Furthermore, a trend in age toward more severe HY 
stages for older age groups was observed in the outpatient 
samples. In each age category, male patients were on av-
erage at slightly higher stages of the disease than women 
(data available at request). As a consequence, the relative 
frequency of the HY stages I and II was lower and the HY 
stage V was higher after the standardization in all outpa-
tient samples. A limitation of this analysis was that the Ta
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outpatient samples are not representative for the German 
population of patients with PD for other reasons than age 
or gender. For instance, patients living in nursing homes 
or severely affected patients not able to visit an office-
based physician are under-represented in all considered 
outpatient samples.
Conclusion
We contributed to the current description of the epi-
demiology of PD in Germany by providing up-to-date 
age- and gender-specific as well as severity-based preva-
lence figures. Such figures are urgently needed for plan-
ning resource allocation and assessing the disease burden. 
For instance, the calculation of the proportion of patients 
with late-stage PD can often only roughly be estimated 
due to the lack of HY- and duration-specific epidemio-
logical studies. However, the validity of the prevalence 
figures remains unclear, since they are mainly based on 
cross-sectional studies from few European countries and 
selective patient samples in Germany. Therefore, high 
quality studies determining population-based figures on 
the distribution of severity figures and non-motor symp-
toms of PD are recommended to face the increasing de-
mand of health services for the oldest and most severely 
disabled patients on a rational basis.
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Table 5. Pooled prevalences for the population younger than 60 years stratified by year and country
Pooled prevalence of PD/100,000 (95% CI)
age <50 years age 50–59 years
males females males females
Year of the studies
Before 1990 5.44 (2.89–8.81) 3.92 (1.82–6.83) 166 (124–213) 126 (86–173)
From 1990 until 2000 4.81 (1,69–9.53) 3.34 (0.40–9.11) 141 (105–182) 82 (56–114)
After 2000 4.25 (1.56–8.26) 1.31 (0.10–3.88) 87 (54–130) 65 (36–102)
Country of study
Italy 5.36 (0.57–15.0) 4.19 (0.44–15.9) 207 (172–245) 176 (152–203)
United Kingdom 4.92 (2.56–8.03) 1.58 (0.41–3.52) 107 (83–133) 57 (40–77)
PD, Parkinson’s disease.
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